NCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Ohio State University Comprehensive Cancer Center
Linnaeus Therapeutics, Inc.
Peking University Cancer Hospital & Institute